<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235157</url>
  </required_header>
  <id_info>
    <org_study_id>EE01-01</org_study_id>
    <nct_id>NCT00235157</nct_id>
  </id_info>
  <brief_title>A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.</brief_title>
  <acronym>GREAT</acronym>
  <official_title>Palmaz Genesis Peripheral Stainless Steel Balloon Expandable Stent, Comparing a Sirolimus Coated Versus an Uncoated Stent in REnal Artery Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the safety and performance of the Palmaz
      Genesis™ balloon expandable stent, with or without sirolimus coating in the treatment of
      renal artery stenosis, measured at 6 months follow up via angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, prospective, controlled, non-randomized investigational feasibility study. One
      hundred (100) patients with de novo or restenotic renal artery lesions consisting of &gt;= 50%
      stenosis and reference vessel of &gt;= 4.0 to &lt;= 8.0 mm in diameter will be sequentially
      included, 50 without sirolimus coating, followed by 50 with sirolimus coating Palmaz
      GenesisTM. Patients will be followed for 24 months post-procedure, with all patients having
      clinical assessments at discharge, 1,6, 12 and 24 months. This study will be conducted at
      twelve investigational sites.

      It is anticipated that the total length of time required to complete the study will be 46
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of the angiographical in-stent minimal lumen diameter</measure>
    <time_frame>6-months follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical primary patency</measure>
    <time_frame>discharge, 1, 6 and 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural success</measure>
    <time_frame>post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worsening renal function</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood pressure measurement</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>significant embolic events causing end-organ damage</measure>
    <time_frame>30 days, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Renal Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus-eluting Palmaz Genesis peripheral stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting Palmaz Genesis peripheral stent</intervention_name>
    <description>treatment of renal artery stenosis with a renal stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Palmaz Genesis Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical indication for renal artery revascularization of atherosclerotic renal artery
             stenosis &gt;=50% as measured by operator or estimated original vessel diameter, based on
             healthy vessel segment and contralateral side.

          2. The reference vessel renal artery must be &gt;= 4mm and &lt;= 8 mm by visual estimate.

          3. The patient must have a baseline serum creatinine of &lt;= 5.0 mg/dl.

        Exclusion Criteria:

          1. Total occlusion of the renal artery.

          2. Lesions which would require more than 2 stents.

          3. Lesions which are in arteries to transplanted or bypassed kidneys.

          4. Abdominal aortic aneurysm &gt; 4.0 cm in diameter.

          5. Patients with ASA classification &gt;=4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Zähringer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätskliniken Köln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Sapoval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Européen Georges Pompidou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter M Pattynama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC Rotterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75 015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Köln</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Zähringer M, Sapoval M, Pattynama PM, Rabbia C, Vignali C, Maleux G, Boyer L, Szczerbo-Trojanowska M, Jaschke W, Hafsahl G, Downes M, Bérégi JP, Veeger NJ, Stoll HP, Talen A. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther. 2007 Aug;14(4):460-8.</citation>
    <PMID>17696619</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>August 5, 2008</last_update_submitted>
  <last_update_submitted_qc>August 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll, Director Clinical Affairs</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

